Technical Meeting:
Barriers in HPV vaccination & cervical screening programmes
Antwerp, Belgium – June 2016
Meeting Objectives
- To review cultural, infrastructural and financial barriers that impact implementation of vaccination and screening programmes.
- To review the adverse events profile following HPV vaccination.
- To update the points of view regarding safety issues and describe new developments.
- To discuss the impact of safety issues and crises in an international perspective.
- To review factors impacting adherence to cervical screening programmes.
- To learn from country initiatives in HPV vaccine safety monitoring and HPV screening adherence.
- To propose strategies to counter vaccination and screening hesitancy and to build public confidence in the HPV prevention programs
- To discuss a new approach to implement HPV prevention and control: HPV-Faster.
Background Document
DAY 1 – Monday, June 27th 2016
SESSION 1: OPENING
Chairs: Lauri Markowitz & Pierre Van Damme
- Welcome, introduction of the participants, review of the meeting objectives & programme
Alex Vorsters, University of Antwerp
SESSION 2: INTERPRETATION OF SAFETY DATA
Chairs: Lauri Markowitz & Pierre Van Damme
- HPV vaccines: past, present and future safety issues undertaken by the Global Advisory Committee on Vaccine Safety (GACVS)
Robert Pless, Public Health Agency of Canada GACVS
- Review of Safety data of initials clinical trials
Pier Luigi Lopalco, University of Pisa (Italy)
- Exploring incidence rates of Guilliain Barré (GBS), Chronic Fatigue (CFS) and Postural Orthostatic Tachycardia Syndrome (POTS) prior to HPV vaccine introduction among adolescent girls in Finland
Hannah Nohynek, National Institute for Health and Welfare (Finland)
- Vaccine safety – Mortality after HPV vaccination observed in RCTs
Marc Arbyn, Scientific Institute of Public Health (Belgium)
- Questions & Discussion
SESSION 3: VACCINE CONFIDENCE
Chairs: Pier Luigi Lopalco & Monica Chaturvedi
- The state of vaccine confidence in the world & factors influencing vaccine acceptance (incl. the global spread of HPV rumours)
Heidi Larson and Emilie Karafillakis, London School of Hygiene and Tropical Medicine (UK)
- Questions and Discussion
- Strategies to measure and address vaccine hesitancy
Heidi Larson and Emilie Karafillakis
- Questions & Discussion
SESSION 4: HPV VACCINATION PROGRAMS: COUNTRY EXPERIENCES AND LESSONS LEARNT
Chairs: Margaret Stanley & Joakim Dillner
- The Scottish HPV vaccine programme – why is it a success story?
Kevin Pollock, Health Protection Scotland
- Barriers in HPV Vaccination in India
Monica Chaturvedi, Public Health Foundation (India)
- The Japanese HPV vaccine tragedy and the take-home message
Sharon Hanley, Hokkaido University Graduate School of Medicine (Japan)
- Implementing the HPV programme in England – what mattered?
Joanne Yarwood, National Infection Service, Public Health England (UK)
- HPV Vaccination in the United States, the First 10 Years: Policy, Program and Monitoring
Lauri Markowitz, Centre for Disease Control & Prevention (CDC) (US)
- Belgium
Geert Top, Flemish Agency for Care and Health (Belgium)
- Questions & Discussion
SESSION 5:HPV VACCINATION PROGRAMS: COUNTRY EXPERIENCES AND LESSONS LEARNT (cont’d)
Chairs: Mira Kojouharova & Paolo Bonanni
- Romania
Patriciu Achimas, The Oncology Institute “Prof. Dr. Ion Chiricuta” (Romania)
- HPV vaccination experience in 45 low and middle-income countries: lessons learnt
Kate Gallagher (presenting on behalf of Deborah Watson-Jones), London school of Hygiene and Tropical Medicine (UK)
- E-learning initiative on vaccine safety assessment focused in HPV vaccines
Xavier Bosch, Catalanian Institute of Ocology (Spain)
- Questions & Discussion
DAY 2: Tuesday, June 28, 2016
SESSION 6: HPV VACCINATION PROGRAMS: COUNTRY EXPERIENCES AND LESSONS LEARNT (cont’d)
Chairs: Liudmila Mosina & Mario Poljak
- Denmark
Kåre Mølbak, Statens Serum Institute, Division of Epidemiology and Disease Surveillance (Denmark)
SESSION 7: BARRIERS AND OPPORTUNITIES IN HPV SCREENING PROGRAMS
- Using behavioural science to increase participation in cervical cancer prevention
Laura Marlow, Department of Epidemiology and Public Health, UCL (UK)
- Mobilizing resources for scale-up of vaccination and screening/preventive treatment: Cervical Cancer Action and the new global Initiative
Scott Wittet, PATH (US)
- Social determinants of health associated with cervical cancer screening; focus on barriers/challenges/facilitators with vulnerable or marginalized women
Pamela Wakewich, Lakehead University (Canada)
- HPV screening barriers in Romania
Patriciu Achimas, The Oncology Institute “Prof. Dr. Ion Chiricuta” (Romania)
- Questions & Discussion
SESSION 8: HPV-FASTER: BROADENING THE SCOPE FOR PREVENTION OF HPV-RELATED CANCER
Chairs: Susan Wang & Marc Arbyn
- Introduction
Xavier Bosch Catalanian Institute of Ocology (Spain)
- Acceptability of HPV vaccination in adult women: Coheahr study
Silvia de Sanjose, Catalanian Institute of Ocology (Spain)
- HPV and cervical cancer control: epidemiological modelling
Iacopo Baussano, International Agency (France)
SESSION 9: CONCLUSION OF THE MEETING
Chairs: Mark Kane & Xavier Bosch
- Conclusions of the meeting
Marc Baay